Dr. Reddy's Laboratories RDY
US equityMarket cap rank #1259Drug Manufacturers - Specialty & GenericInfectious DiseaseCannabis & Hemp
$14.89 +$0.06 (+0.40%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $15.00 +0.74%
Open$14.88
Prev close$14.83
Day range$14.86 – $15.10
Volume1.75M
Market cap$12.41B
P/E (TTM)41.4
Dividend yield0.56%
Earnings
Average move on report day±2.7%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+3.2%
Worst reaction-9.4%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2027/Q2 | 23 Oct 2026 | None | ±8.7% | -0.15% | Within range |
| 2027/Q1 | 22 Jul 2026 | None | ±8.0% | -9.39% | Bigger than priced |
| 2026/Q4 | 12 May 2026 | None | – | -5.18% | – |
| 2026/Q3 | 21 Jan 2026 | None | ±10.6% | +2.63% | Within range |
| 2026/Q2 | 24 Oct 2025 | None | ±11.6% | -0.27% | Within range |
| 2026/Q1 | 23 Jul 2025 | None | – | +1.32% | – |
| 2025/Q4 | 9 May 2025 | None | ±15.0% | +1.67% | Within range |
| 2025/Q3 | 23 Jan 2025 | None | ±12.6% | -6.23% | Within range |
| 2025/Q2 | 5 Nov 2024 | None | ±4.6% | -1.27% | Within range |
| 2025/Q1 | 29 Jul 2024 | None | ±7.4% | +0.99% | Within range |
| 2024/Q4 | 7 May 2024 | Pre Market | ±5.8% | -4.73% | Within range |
| 2024/Q3 | 30 Jan 2024 | Pre Market | ±7.7% | -0.93% | Within range |
| 2024/Q2 | 27 Oct 2023 | Pre Market | ±5.9% | +0.70% | Within range |
| 2024/Q1 | 26 Jul 2023 | Pre Market | ±4.8% | +3.25% | Within range |
| 2023/Q4 | 10 May 2023 | Pre Market | ±7.2% | -3.01% | Within range |
| 2023/Q3 | 25 Jan 2023 | Pre Market | ±9.1% | +0.89% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/FY
By business line
By region
Fundamentals
Latest reported quarter: Q2, ended Sep 2026 · reported in INR
Revenue₹86.71B-1.5% YoY
Operating profit₹12.81B-29.5% YoY
Net profit₹9.13B-36.0% YoY
Diluted EPS₹11.10-35.7% YoY
Free cash flow₹959.00M-82.4% YoY
Operating cash flow₹5.28B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin49.5%
Operating margin9.5%
Net margin8.5%
Return on equity7.5%
Return on assets5.0%
Return on invested capital6.2%
Current ratio1.93
Liabilities / assets32.2%
Cash & investments₹76.24B
Total debt₹72.29B
Net cash (debt)₹3.96B
Free cash flow / sales1.4%
No comments yet — be the first to weigh in on RDY.
Sign in to join the discussion.